In an interview with The Rheumatologist, J. Larry Jameson, MD, PhD, discusses the benefits and complications of precision medicine for rheumatologists and their patients, including advances in genetics, diagnostic tools and targeted treatments…
Richard Quinn is an award-winning journalist with 15 years’ experience. He has worked at the Asbury Park Press in N.J. and The Virginian-Pilot in Norfolk, Va., and currently is managing editor for a leading commercial real estate publication. His freelance work has appeared in The Jewish State, The Hospitalist, The Rheumatologist, ACEP Now and ENT Today. He lives in New Jersey with his wife, new son and three cats.
Articles by Richard Quinn
Most Rheumatologists Want FDA to Better Regulate Biosimilars
In a survey, the Coalition of State Rheumatology Organizations found a consensus among rheumatologists that the FDA should increase safety for biosimilar therapies via naming and labeling regulations…
Personal Beliefs Affect Medication Adherence for RA Patients
A recent British study concluded that determining a rheumatoid arthritis patient’s personal beliefs about medication could aid rheumatologists in regularly addressing medication adherence during visits.
Proposed Medicaid Rule May Benefit Rheumatologists
The Centers for Medicare & Medicaid Services is attempting to update the reimbursement process for Medicaid, which might relieve administrative burdens on specialists and improve access to services.
Institute of Medicine Recommends Changes in Graduate Medical Education
Questions, concerns and spirited debate have surrounded the Graduate Medical Education (GME) system for decades. The program that trains nearly 120,000 physicians per year is under constant scrutiny.1 Changes to the political landscape, combined with ongoing efforts by health industry payers and regulators to squeeze inefficiency out of the system, have kept the GME in…
Weight Loss May Predict Early Death in RA Patients
According to a new study, patients with RA experiencing weight loss unrelated to exercise may be at risk of premature death.
High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
The high out-of-pocket costs of biologic disease modifying antirheumatic drugs (DMARDs) place “enormous financial strain” on Medicare beneficiaries and may limit therapy adherence, according to the lead author of a national investigation into Part D coverage and cost-sharing structures. Recently published online in Arthritis & Rheumatology, the study analyzed 2,737 Part D plan formularies for…
Rheumatoid Arthritis and Pregnancy
Research shows women with RA at risk of preterm birth
Prior Authorization Requests Delay or Prevent Delivery of Needed Meds
Rheumatologist denounces common practice as a time-draining impediment to patient care
The ACR Recommends Cautious Approach as Biosimilars Enter U.S. Market
With the U.S. FDA’s first approval of a biosimilar drug earlier this month, rheumatologists stress the need to ensure safety, efficacy of such drugs in treating rheumatic diseases
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 16
- Next Page »